Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas

Cancer Research

Volumn 59, Issue 23, 1999, Pages 5995-5998

  Ueki, Keisuke ^a   Wen Bin, Chen ^a   Narita, Yoshitaka ^a   Asai, Akio ^a   Kirino, Takaaki ^a,b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN;

ARTICLE; CARCINOGENESIS; CHROMOSOME 22Q; CLINICAL ARTICLE; FEMALE; FRAMESHIFT MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; MOLECULAR GENETICS; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 22; EXONS; FEMALE; GENE DELETION; GENES, NEUROFIBROMATOSIS 2; HOMOZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM PROTEINS; NEUROFIBROMIN 2; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE DELETION;

EID: 0033431053     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ruttledge, M. H., Sarrazin, J., Rangaratnam, S., Phelan, C. M., Twist, E., Merel, P., Delattre, O., Thomas, G., Nordenskjold, M., Collins, V. P., Dumarski, J. P., and Rouleau, G. A. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet., 6: 180-184, 1994.
2. Papi, L., De Vitis, L. R., Vitelli, F., Ammannati, F., Mennonna, P., Montali, E., and Bigozzi, U. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum. Genet., 95: 347-351, 1995.
3. Lekanne Deprez, R. H., Bianchi, A. B., Groen, N. A., Seizinger, B. R., Hagemeijer, A., van Drunen, E., Bootsma, D., Koper, J. W., Avezaat, C. J., Kley, N., and Zwarthoff, E. C. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am. J. Hum. Genet., 54: 1022-1029, 1994.
4. De Vitis, L. R., Tedde, A., Vitelli, F., Ammannati, F., Mennonna, P., Bigozzi, U., Montali, E., and Papi, L. Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum. Genet., 97: 632-637, 1996.
5. Wellenreuther, R., Kraus, J. A., Lenartz, D., Menon, A. G., Schramm, J., Louis, D. N., Ramesh, V., Gusella, J. F., Wiestler, O. D., and von Deimling, A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am. J. Pathol., 146: 827-832, 1995.
6. Akagi, K., Kurahashi, H., Arita, N., Hayakawa, T., Monden, M., Mori, T., Takai, S., and Nishisho, I. Deletion mapping of the long arm of chromosome 22 in human meningiomas. Int. J. Cancer, 60: 178-182, 1995.
7. Louis, D. N., Ramesh, V., and Gusella, J. F. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol., 5: 163-172, 1995.
8. Kimura, Y., Koga, H., Araki, N., Mugita, N., Fujila, N., Takeshima, H., Nishi, T., Yamashima, T., Saldo, T. C., Yamasaki, T., Moritake, K., Saya, H., and Nakao, M. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat. Med., 4: 915-922, 1998.
9. Lahiri, D. K., and Nurnberger, J. I., Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res., 19: 5444, 1991.
10. Jacoby, L. B., MacCollin, M., Louis, D. N., Mohney, T. Rubio, M. P., Pulaski, K., Trofatter, J. A., Kley, N., Seizinger, B., Ramesh, V., and Gusella, J. F. Exon scanning for mutation of the NF2 gene in schwannomas. Hum. Mol. Genet., 3: 413-419, 1994.
11. von Deimling, A., Eibl, R. H., Ohgaki, H., Louis, D. N., von Ammon, K., Petersen, I., Kleihues, P., Chung, R. Y., Wiestler, O. D., and Seizinger, B. R. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res., 52: 2987-2990, 1992.
12. Saido, T. C, Nagao, S., Shiramine, M., Tsukaguchi, M., Sorimachi, H., Murofushi, H., Tsuchiya, T., Ito, H., and Suzuki, K. Autolytic transition of μ-calpain upon activation as resolved by antibodies distinguishing between the pre-and post-autolysis forms. J. Biochem. (Tokyo). 11: 81-86, 1992.
13. Nagao, S., Saido, T. C., Akita, Y., Tsuchiya, T., Suzuki, K., and Kawashima, S. Calpain-calpastatin interactions in epidermoid carcinoma KB cells. J. Biochem. (Tokyo), 115: 1178-1184, 1994.
14. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herach, J., Jenkins, R., Westra, W., Futter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L. Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidranski, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
15. Knudson, A. G., Jr. Genetic predisposition to cancer. Cancer Detect. Prev., 7: 1-8, 1984.
16. Joseph, J. T., Lisle, D. K., Jacoby, L. B., Paulus, W., Barone, R., Cohen, M. L., Roggendorf, W. H., Bruner, J. M., Gusella, J. F., and Louis, D. N. NF2 gene analysis distinguishes hemangiopericytoma from meningioma. Am. J. Pathol., 147: 1450-1455, 1995.
17. Zucman-Rossi, J., Legoix, P., Der Sarkissian, H., Cheret, G., Sor, F., Bernardi, A., Cazes, L., Giraud, S., Ollagnon, E., Lenoir, G., and Thomas, G. NF2 gene in neurofibromatosis type 2 patients. Hum. Mol. Genet., 7: 2095-2101, 1998.
18. Ruttledge, M. H., Xie, Y. G., Han, F. Y., Peyrard, M., Collins, V. P., Nordenskjold, M., and Dumanski, J. P. Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer. 10: 122-130, 1994.
19. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
20. Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., Ramsay, D. A., and Louis, D. N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst., 90: 1473-1479, 1998.
21. Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bolliger, C. T., Kauczor, H. U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., and Huber, C. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther., 9: 2075-2082, 1998.
22. Stemmer-Rachamimov, A. O., Xu, L., Gonzalez-Agosti, C., Burwick, J. A., Pinney, D., Beauchamp, R., Jacoby, L. B., Gusella, J. F., Ramesh, V., and Louis, D. N. Universal absence of merlin, but not other ERM family members, in schwannomas. Am. J. Pathol., 151: 1649-1654, 1997.